Martin Sharpless, AIA is the Capital Projects Director in charge of R&D facilities capital programs for multiple US and UK locations, at AstraZeneca Pharmaceuticals LP. He is a strategic project development specialist, working with clients, design, construction, development and investment partners to define and execute projects. Mr. Sharpless has experience with project design, construction, design build, development projects and public private partnerships (P3) project delivery.
Mr. Sharpless was previously Vice President with Skanska USA Building Inc. and Gilbane Building Company respectively, providing Principal-level client, AEC and P3 partner leadership since 1998. He is an active member with LAI, AIA, USGBC, ISPE. Prior to his construction career Mr. Sharpless, a registered architect, was an Associate with Kling Stubbins in Philadelphia and opened their Washington, DC office in 1995. He started his career at Ballinger Architects, and earned a Bachelor of Science and Bachelor of Architecture at Pennsylvania State University.